Dutch drugmakers group debates media

16 February 2009

The Netherlands' drugmakers association, Nefarma, is holding a debate at the Glazen Zaaldebat in The Hague on February 24 concerning the  "turbulent relationship" between the pharmaceutical sector and the  media. The event will bring together representatives of both parties and  is designed to allow each side to set out its critique of the other and  to respond with possible ways forward.

Representing Nefarma will be its secretary general, Luc Debruyne, while  Cor Groeneweg, head of public affairs and public relations for the  insurance union (Verbond van Verzekeraars), will present the viewpoint  of someone with both journalistic and corporate affairs experience. On  the media side will be Kees Driehuis, editor of a television documentary  program, Zembla, and Simon Rozendaal, a journalist with the Elsiever  group. The chairman will be Jeroen Smit, a journalist and author.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight